Preferences help
enabled [disable] Abstract
Number of results
2010 | 5 | 4 | 431-436
Article title

Peripheral blood CD4+CRTH2+ cells in advanced stage non small cell lung cancer

Title variants
Languages of publication
To investigate CD4+CRTH2+ cells in peripheral blood in advanced stage non small cell lung cancer (NSCLC) patients. Forty-six patients with advanced stage NSCLC, who are chemotherapy or radiotherapy naïve, and 17 healthy volunteers, were enrolled in this study. The study was performed using flow cytometry and a complete blood cell counter analyser. CD4+ T cell percentage, CD4/CD8 ratio, CRTH2+CD4+ cell percentages, counts, and mean fluorescein intensity (MFI) and hematological parameters were evaluated in both groups. A survival analysis was performed to compare the patients with high CD4+CRTH2+ cell percentage and those with low CD4+CRTH2+ percentage. CD4+ T cell percentage in total lymphocytes and the CD4/CD8 ratio were lower in the patient group than in the control group. The absolute CD8 T cell count was higher in the patient group than in the control group, whereas the total T cells was not different. The CRTH2+ cell percentage in CD4+ T cells (7.96% ± 6.21% vs 3.37% ± 3.55%; respectively; p: 0,001) and the absolute count of CRTH2+CD4+ cells ( 97 mm-3 ± 109 mm-3 vs 37 mm-3 ± 38 mm-3, respectively; p: 0,033) in the patient group were higher than in the control group, but CRTH2-PE MFI values were not different between groups. Cox regression analysis did not show that CRTH2+CD4+ cell count or percentage is an independent prognostic factor. The study found that CRTH2 expression of CD4+ T cells and CRTH2+CD4+ cell number are higher in the peripheral blood of NSCLC patients than in that of healthy subjects. Further studies that explore the biological significance of high CD4+CRTH2+ cells in lung cancer patients, should be pursued.
Physical description
1 - 8 - 2010
30 - 5 - 2010
  • [1] Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147–166[Crossref]
  • [2] Nagata K, Hirai H. The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 2003;69:169–177[Crossref]
  • [3] Tanaka K, Hirai H, Takano S, Nakamura M, Nagata K. Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun 2004;316:1009–1014[Crossref]
  • [4] Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999;459:195–199[Crossref]
  • [5] Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via even transmembrane receptor CRTH2. J Exp Med 2001;193:255–261[Crossref]
  • [6] Ellyard JI, Simson L, Parish CR. Th 2-mediated antitumour immunity: friend or foe? Tissue Antigens 2007;70:1–11[WoS][Crossref]
  • [7] Takanami I, Takeuchi K, Gika M. Immunohistochemical detection of eosinophilic infiltration in pulmonary adenocarcinoma. Anticancer Res 2002;22:2391–2396
  • [8] Cosmi L, Annunziato F, Galli MIG, Maggi RME, Nagata K, Romagnani S. CRTH 2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 2000;30:2972–2979<2972::AID-IMMU2972>3.0.CO;2-#[Crossref]
  • [9] Wang YH, Ito T, Wang YH, Homey B, Watanabe N, Martin R et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin activated dendritic cells. Immunity 2006;24:827–838[Crossref]
  • [10] Kim N, Luster AD. Regulation of immune cells by eicosanoid receptors. Scientific World Journal 2007;7:1307–1328 [Crossref]
  • [11] Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007;204:1037–1047[WoS][Crossref]
  • [12] Venet F, Lepape A, Debard AL, Bienvenu J, Bohe J, Monneret G. The Th2 response as monitored by CRTH2 or CCR3 expression is severely decreased during septic shock. Clin Immunol 2004;113:278–284[Crossref]
  • [13] Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387–393[Crossref]
  • [14] Chu Y, Xia M, Lin Y, Li A, Wang Y, Liu R et al. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 2006;13:510–519[Crossref]
  • [15] Mautner J, Jaffee EM, Pardoll DM. Tumorspecific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 2005;115:752–759[Crossref]
  • [16] Tepper RI, Coffman RL, Leder P. An eosinophildependent mechanism for the antitumor effect of interleukin-4. Science 1992;257:548–551[Crossref]
  • [17] Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A et al. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659–5673
  • [18] Saleh M, Davis ID, Wilks AF. The paracrine role of tumour-derived mIL-4 on tumour associated endothelium. Int J Cancer 1997;72:664–672<664::AID-IJC19>3.0.CO;2-B[Crossref]
  • [19] Schuler T, Kornig S, Blankenstein T. Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med 2003;198:1487–1493[Crossref]
  • [20] Lebel-Binay S, Laguerre B, Quintin-Colonna F, Conjeaud H, Magazin M, Miloux B et al. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 1995;25:2340–2348[Crossref]
  • [21] Ma HL, Whitters MJ, Jacobson BA, Donaldson DD, Collins M, Dunussi-Joannopoulos K. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo. Int Immunol 2004;16:1009–1017
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.